

# INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Docket Number (Optional)

42830-00234

Application Number

09/888,235

Applicant(s)

BLONDER et al.

Filing Date

June 22, 2001

Group Art Unit

1648

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
Ble	A	6,201,072	3/13/01	RATHI et al.	525	415	TECH CENTER 1600/2900 AUG 29 2001 RECEIVED
Ble	B	6,117,949	9/12/00	RATHI et al.	525	415	
Ble	C	6,004,573	2/21/99	RATHI et al.	424	426	
Ble	D	5,980,912	11/9/99	PODOLSKI et al.	424	278.1	
Ble	E	5,939,485	8/17/99	BROMBERG et al.	525	556	
Ble	F	5,912,000	6/15/99	PODOLSKI et al.	424	278.1	
Ble	G	5,861,174	1/19/99	STRATTON et al.	424	484	
Ble	H	5,902,110	5/11/99	ALFANO et al.	433	215	
Ble	I	5,702,717	12/30/97	CHA et al.	424	425	
Ble	J	4,971,956	1/20/90	SUZUKI et al.	514	55	

## FOREIGN PATENT DOCUMENTS

REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						YES	NO
Ble	K	WO 00/56362	9/28/00	WIPO			
	L	WO 00/56361	9/28/00	WIPO			
	M	WO 99/65521	12/23/99	WIPO			
	N	WO 99/32135	7/1/99	WIPO			

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Ble	O	Malakoff, "Aluminum is Put on Trial as a Vaccine Booster," Science, 2000. 288: 1323.
Ble	P	McNeela, E.A. et al. A mucosal vaccine against diphtheria: formulation of cross reacting material (CRM197) of diphtheria toxin with chitosan enhances and systemic antibody and Th2 responses following nasal delivery. 2001. Vaccine 19: 1188-1198.

EXAMINER

Asgharhi

DATE CONSIDERED

10/15/02

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

TECH CENTER 1600/2900  
AUG 29 2001

# INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Docket Number (Optional)

42830-00234

Application Number

09/888,235

Applicant(s)

BLONDER et al.

Filing Date

June 22,2001

Group Art Unit

1648

\*EXAMINER  
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Q	Seferian, P.G. and M.L. Martinez. Immune stipulating activity of two new chitosan containing adjuvant formulations. 2001. Vaccine 19: 661-668.
R	Edelman, R., An Overview of Adjuvant Use, in "Vaccine Adjuvants" Ed. D.T. O'Hagan, Humana Press, Totowa, NJ. 2000. 1-27.
S	Baldrige, J. R. et al. Monophosphoryl lipid A enhances mucosal and systemic immunity to vaccine antigens following intranasal administration. 2000. Vaccine 18: 2416-2425.
T	Goto, N. et al. Safety evaluation of recombian cholera toxin B subunit produced by Bacillus brevis as a mucosal adjuvant. 2000. Vaccine 18: 2164-2171.
U	McCluskie, M. et al. Intranasal Immunization of Mice with CpG DNA Induces Strong Systemic and Mucosal Responses That Are Influenced by Other Mucosal Adjuvants and Antigen Distribution. 2000. Mol. Med. 6: 867-877.
V	Bacon, A. et al. Carbohydrate biopolymers enhance antibody responses to mucosally delivered antigens. 2000. Infection and Immunity. 68: 5784-5770.
W	Witschi, C. and R.J. Mrsny. In vitro Evaluation of Microparticles and Polymer Gels for Use as Nasal Platforms for Protein Delivery. 1999. Pharmaceutical Research 16: 382-390.
X	Barchfield, G.L. et al. The adjuvants MF59 and LT-K63 enhance the mucosal and systemic immunogenicity of subunit influenza vaccine administered intranasally in mice. 1999. Vaccine 17: 695-704.
Y	Isaka, M. et al. Systemic and mucosal immune responses of mice to aluminum-adsorbed or aluminum-non-adsorbed tetanus toxoid administered intranasally with recombian cholera toxin B subunit. 1998. Vaccine 16: 1620-1626.
Z	Jabbal-Gill et al. Stimulation of mucosal and systemic antibody response against Bordatella pertussis filamentous haemagglutinin and recombian pertussis toxin after nasal administration with chitosan in mice. 1998. Vaccine 16: 2039-2046.
AA	Horner, A.A. et al. Immunostimulatory DNA is a Potent Mucosal Adjuvant. 1998. Cell. Immunol. 190: 77-82.
BB	Lowrey, L. et al. Induction of Tolerance via the Respiratory Mucosa. Int. Arch. Allergy Immunol. 1998. 116: 93-102.

EXAMINER

Daogun hi

DATE CONSIDERED

10/15/2002

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

# INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Docket Number (Optional)

42830-00234

Application Number

09/888,235

Applicant(s)

BLONDER et al.

Filing Date

June 22, 2001

Group Art Unit

1648

TECH CENTER 1600/2900

AUG 29 2001

RECEIVED

\*EXAMINER  
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

CC

Yamamoto, S. et al. A nontoxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal immunity. 1997. Proceedings of the National Academy of Sciences of the United States of America. 94: 5267-5272.

DD

Neutra, M.R. et al. Antigen Sampling Across Epithelial Barriers and Induction of Mucosal Immune Responses. 1996. Ann. Rev. Immunol. 14: 275-300.

EE

Levi, R. et al. Intranasal immunization of mice against influenza with synthetic peptides anchored to proteosomes. 1995. Vaccine: 13: 1353-1359.

FF

Pizza, M. et al. A Genetically Detoxified Derivative of Heat-labile Escherichia Coli Enterotoxin Induces Neutralizing Antibodies Against the A Subunit. 1994. J. Exp Med 180, 2147-2153.

GG

Illum, L. et al. Chitosan as a Novel Nasal Delivery System for Peptide Drugs. 1994. Pharmaceutical Research 11: 1186-1189.

HH

Tamura, S. et al. Synergistic action of cholera toxin B subunit (and Escherichia coli heat-labile toxin B subunit) and a trace amount of cholera whole toxin as an adjuvant for nasal influenza vaccine. 1994. Vaccine 12: 419-426.

II

Holmgren, J. et al. Cholera toxin and cholera B subunit as oral-mucosal adjuvant and antigen vector systems. 1993. Vaccine 11: 1179-1184.

JJ

McGhee, J.R. et al. The mucosal immune system: from fundamental concepts to vaccine development. 1992. Vaccine: 10: 75-88.

KK

McNicholl, J.M. et al. Enhancement of HIV Type 1 Vaccine Immunogenicity by Block Copolymer Adjuvants. I. Induction of High-Titer, Long-Lasting, Cross-Reactive Antibodies of Broad Isotype, AIDS RESEARCH AND HUMAN RETROVIRUSES, Vol. 14, No. 16, 1998, pp. 1457-1471.

LL

Raghuvanshi, R.S. et al. Biodegradable delivery system for single step immunization with tetanus toxoid. International Journal of Pharmaceutics. 1993. 93: R1-R5.

EXAMINER

Waggoner

DATE CONSIDERED

10/15/2002

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)				Docket Number (Optional) <b>42830-00234</b>		Application Number <b>09/888,235</b>		
<div style="border: 1px solid black; border-radius: 50%; padding: 10px; display: inline-block;">             APR 12 2002              PATENT &amp; TRADEMARK OFFICE           </div>				Applicant(s) <b>BLONDER - SUPPLEMENTAL -</b>				
				Filing Date <b>June 22, 2001</b>		Group Art Unit <b>1648</b>		
U.S. PATENT DOCUMENTS								
*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
<i>Doc</i> ↓	A	2001/0044416 A1	11/22/01	McCLUSKIE et al.	514	44	RECEIVED APR 16 2002 TECH CENTER 1600/2900	
	B	6,239,116 B1	5/29/01	KRIEG et al.	514	44		
	C	6,218,148 B1	4/17/01	ZSEBO et al.	435	69.5		
	D	6,207,646	3/27/01	KRIEG et al	514	44		
	E	6,086,899	7/11/00	BALASUBRAMANIAN et al.	424	280.1		
	F	5,071,644	12/10/01	VIEGAS et al.	514	772.7		
	G	5,593,683	1/14/97	VIEGAS et al.	424	427		
FOREIGN PATENT DOCUMENTS								
	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
							YES	NO
<i>Doc</i> ↓	H	WO 01/22972 A2	4/4/01	PCT				
	I	WO 01/12218 A1	2/22/01	PCT				
	J	WO 98/06438	2/19/98	PCT				
	K	WO 97/20576	6/12/97	PCT				
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)								
<i>Doc</i> ↓	L	Lemieux, P. et al., A combination of poloxamers increases gene expressions of plasmid DNA in skeletal muscle, GENE THERAPY, 2000, Vol. 7, pp.986-991.						
	M	Miyazaki, S. et al., Sustained-Release and Intragastric-floating Granules of Indomethacin Using Chitosan in Rabbits, CHEM. PHARM. BULL, 1998 Vol. 36 (10), pp. 4033-4038.						
EXAMINER				DATE CONSIDERED				
<i>Daogunh</i>				<i>10/15/02</i>				
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								

105 #5